GlassScriptPhysician profile
Amber Lovitt
NPI 1518506104
$1,351.83
in general payments reported to CMS, 2019-2025
22 companies · $823 in 2025
The $823 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.55 · 2022: $178 · 2023: $135 · 2024: $170 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $265.79 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $194.28 | 2025 | |
| Esperion Therapeutics, INC. | $145.04 | 2022-2024 | Nexletol |
| Lilly USA, LLC | $104.36 | 2022-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $81.13 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $76.00 | 2025 | |
| Glaxosmithkline, LLC. | $54.40 | 2025 | Arexvy, Shingrix |
| Pfizer INC. | $54.30 | 2025 | |
| Antares Pharma, INC. | $52.87 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $47.93 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $40.59 | 2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $37.96 | 2024-2025 | Farxiga, Airsupra |
| Acella Pharmaceuticals, LLC | $26.16 | 2025 | NP Thyroid 60 |
| Genentech USA, INC. | $23.27 | 2021 | |
| Hologic Sales and Service, LLC | $22.28 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.31 | 2025 | Auvelity |
| Phadia US INC. | $21.22 | 2025 | Immunocap |
| Xeris Pharmaceuticals, INC. | $20.66 | 2025 | Keveyis |
| Amgen INC. | $16.11 | 2024 | Prolia, Evenity |
| Verity Pharmaceuticals INC. | $15.81 | 2024 | Tlando |
| Tolmar, INC. | $15.65 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $14.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Lovitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.